Numient

RSS

Withdrawn

This medicine's authorisation has been withdrawn

levodopa / carbidopa
MedicineHumanWithdrawn

Slovenian is available via eTranslation, the European Commission's machine translation service.

Translate to Slovenian | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 2 April 2019, the European Commission withdrew the marketing authorisation for Numient (levodopa / carbidopa) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Amneal Pharma Europe Limited, which notified the European Commission of its decision not to market the product in the EU for commercial reasons. 

Numient was granted marketing authorisation in the EU on 19 November 2015 for symptomatic treatment of adult patients with Parkinson’s disease. The marketing authorisation was initially valid for a 5-year period. The product had not been marketed in the EU. 

The European Public Assessment Report (EPAR) for Numient is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (760.76 KB - PDF)

Prikaži

español (ES) (664.35 KB - PDF)

Prikaži

čeština (CS) (734.48 KB - PDF)

Prikaži

dansk (DA) (661.04 KB - PDF)

Prikaži

Deutsch (DE) (665.21 KB - PDF)

Prikaži

eesti (ET) (660.8 KB - PDF)

Prikaži

ελληνικά (EL) (765.87 KB - PDF)

Prikaži

français (FR) (664.34 KB - PDF)

Prikaži

hrvatski (HR) (686.65 KB - PDF)

Prikaži

italiano (IT) (661.99 KB - PDF)

Prikaži

latviešu (LV) (738.18 KB - PDF)

Prikaži

lietuvių (LT) (1.25 MB - PDF)

Prikaži

magyar (HU) (733.46 KB - PDF)

Prikaži

Malti (MT) (743.54 KB - PDF)

Prikaži

Nederlands (NL) (662.11 KB - PDF)

Prikaži

polski (PL) (692 KB - PDF)

Prikaži

português (PT) (663.31 KB - PDF)

Prikaži

română (RO) (688.99 KB - PDF)

Prikaži

slovenčina (SK) (738.22 KB - PDF)

Prikaži

slovenščina (SL) (730.81 KB - PDF)

Prikaži

suomi (FI) (661.6 KB - PDF)

Prikaži

svenska (SV) (662.58 KB - PDF)

Prikaži

Product information

български (BG) (2.27 MB - PDF)

Prikaži

español (ES) (1.22 MB - PDF)

Prikaži

čeština (CS) (1.91 MB - PDF)

Prikaži

dansk (DA) (988.75 KB - PDF)

Prikaži

Deutsch (DE) (1.29 MB - PDF)

Prikaži

eesti (ET) (1.29 MB - PDF)

Prikaži

ελληνικά (EL) (2.32 MB - PDF)

Prikaži

français (FR) (1.31 MB - PDF)

Prikaži

hrvatski (HR) (1.35 MB - PDF)

Prikaži

italiano (IT) (1.28 MB - PDF)

Prikaži

latviešu (LV) (2.04 MB - PDF)

Prikaži

lietuvių (LT) (1.34 MB - PDF)

Prikaži

magyar (HU) (1.91 MB - PDF)

Prikaži

Malti (MT) (1.93 MB - PDF)

Prikaži

Nederlands (NL) (1.27 MB - PDF)

Prikaži

polski (PL) (1.36 MB - PDF)

Prikaži

português (PT) (1.26 MB - PDF)

Prikaži

română (RO) (1.36 MB - PDF)

Prikaži

slovenčina (SK) (1.91 MB - PDF)

Prikaži

slovenščina (SL) (1.92 MB - PDF)

Prikaži

suomi (FI) (1.26 MB - PDF)

Prikaži

svenska (SV) (1.25 MB - PDF)

Prikaži

Íslenska (IS) (1.24 MB - PDF)

Prikaži

norsk (NO) (1.15 MB - PDF)

Prikaži
Latest procedure affecting product information:T/0005
03/08/2018
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (663.12 KB - PDF)

Prikaži

español (ES) (592.52 KB - PDF)

Prikaži

čeština (CS) (641.3 KB - PDF)

Prikaži

dansk (DA) (593.46 KB - PDF)

Prikaži

Deutsch (DE) (596.9 KB - PDF)

Prikaži

eesti (ET) (596.6 KB - PDF)

Prikaži

ελληνικά (EL) (659.83 KB - PDF)

Prikaži

français (FR) (593.43 KB - PDF)

Prikaži

hrvatski (HR) (612.12 KB - PDF)

Prikaži

italiano (IT) (593.46 KB - PDF)

Prikaži

latviešu (LV) (626.17 KB - PDF)

Prikaži

lietuvių (LT) (609.67 KB - PDF)

Prikaži

magyar (HU) (632.86 KB - PDF)

Prikaži

Malti (MT) (621.02 KB - PDF)

Prikaži

Nederlands (NL) (592.57 KB - PDF)

Prikaži

polski (PL) (33.46 KB - PDF)

Prikaži

português (PT) (595.16 KB - PDF)

Prikaži

română (RO) (607.16 KB - PDF)

Prikaži

slovenčina (SK) (622.14 KB - PDF)

Prikaži

slovenščina (SL) (619.27 KB - PDF)

Prikaži

suomi (FI) (595.79 KB - PDF)

Prikaži

svenska (SV) (593 KB - PDF)

Prikaži

Íslenska (IS) (593.23 KB - PDF)

Prikaži

norsk (NO) (592.7 KB - PDF)

Prikaži

Product details

Name of medicine
Numient
Active substance
  • levodopa
  • carbidopa
International non-proprietary name (INN) or common name
  • levodopa
  • carbidopa
Therapeutic area (MeSH)
Parkinson Disease
Anatomical therapeutic chemical (ATC) code
N04BA02

Pharmacotherapeutic group

Anti-Parkinson drugs

Therapeutic indication

Symptomatic treatment of adult patients with Parkinson’s disease

Authorisation details

EMA product number
EMEA/H/C/002611
Marketing authorisation holder
Amneal Pharma Europe Ltd

70 Sir John Rogerson’s Quay
Dublin 2
Ireland

Opinion adopted
24/09/2015
Marketing authorisation issued
19/11/2015
Withdrawal of marketing authorisation
02/04/2019
Revision
3

Assessment history

This page was last updated on

Share this page